Lonza TheraPEAK

Lonza extends TheraPEAK portfolio with AmpliCell cytokines and 293-GT medium for cell and gene therapy manufacturing

Lonza has launched two new products to strengthen its offering for cell and gene therapy developers: TheraPEAK AmpliCell Cytokines and TheraPEAK 293-GT Medium. The additions address critical manufacturing requirements for immune cell expansion and adeno-associated virus (AAV) production, respectively.

Molcure AI drug discovery

Molcure partners with Boehringer Ingelheim to accelerate AI-driven antibody drug discovery

MOLCURE Inc. has announced a multiyear strategic research agreement with Boehringer Ingelheim to discover innovative antibody therapeutics for multiple targets using the Japanese company’s proprietary artificial intelligence platform technology. The collaboration will combine MOLCURE’s AI-driven platform with Boehringer Ingelheim’s expertise in biologics development, aiming to expand the scope and efficiency of antibody drug discovery beyond […]

bio rad Liquichek Opiate Control

Bio-Rad launches enhanced Liquichek Opiate Control

Bio-Rad Laboratories, a global provider of life science research and clinical diagnostics products, has improved its Liquichek quality control product portfolio with the launch of an enhanced version of its Liquichek Opiate Control.

StemInov stem cells

StemInov secures €10.6 million to advance mesenchymal stem cell therapy for severe pneumonia

French biopharmaceutical company StemInov has closed a €10.6 million financing round to support the industrialisation of its stem cell platform and prepare for Phase I/IIa clinical trials targeting severe pneumonia complications. The Nancy and Illkirch-Graffenstaden-based company, which specialises in mesenchymal stem cell (MSC) therapies for inflammatory and autoimmune diseases, expects to initiate patient recruitment in […]

Fig1 skin antigens

Anti-laminin β4 – a new autoantibody marker in pemphigoid disease

Laminin β4 (lamβ4) has been identified as a novel target antigen in anti-p200 pemphigoid, a rare autoimmune disease manifesting with subepidermal blisters. Anti-lamβ4 antibodies bind to the region of the dermal–epidermal junction and demonstrate pathogenic effects. A recombinant-cell indirect immunofluorescence assay has been developed for specific detection of anti-lamβ4 antibodies.

AdobeStock 199128755

Identification of putative breath biomarkers for detection of lymphoma

Volatile organic compounds (VOCs) are released from our bodies in our breath, sweat, blood and urine as a result of metabolic activity and so provide a window on our metabolic and physiological status. These VOCs change in response to disease, providing the potential for disease-specific VOCs in the breath to be used as non-invasive biomarkers […]

Scherm­afbeelding 2025 11 07 om 09.23.35

ACD/Labs expands Katalyst D2D software capabilities for pharmaceutical development

ACD/Labs has released version 25.4 of Katalyst D2D, extending the industry-leading workflow digitalisation software beyond its original high throughput experimentation applications to support process scale-up and material characterisation in pharmaceutical development. The enhanced platform enables pharmaceutical project teams to accelerate the design-make-test-analyse cycle from discovery through to clinical trials.

AdobeStock 1628206991 Omgezet e1762439956239

Point-of-care test for detection of the FKBP12 biomarker at single-molecule level

FK506 (tacrolimus) binding protein 12 (FKBP12) is involved in fundamental cellular processes as well as immunosuppression, neurodegenerative diseases and cancer. Hence, the ability to quickly and easily determine its levels is desirable. CLI caught up with Dr Pitruzzella, Dr Caminati and Prof. Cennamo to find out more about the point-of-care test that they have developed […]

Wexis Atomizer

Wexis introduces Atomizer to enhance section adhesion, precision

Wexis has unveiled the Atomizer, a breakthrough in microtomy workflow designed to enhance section adhesion, precision, and efficiency.

Scherm­afbeelding 2025 11 07 om 12.39.04

OHAUS introduces IVD-compliant centrifuge range with low-impact refrigerant

OHAUS Corporation has introduced a new series of centrifuges designed for in vitro diagnostic applications, featuring natural refrigerant R290 with substantially reduced environmental impact compared to conventional cooling systems.